Literature DB >> 10793090

Eosinophilia of dystrophin-deficient muscle is promoted by perforin-mediated cytotoxicity by T cell effectors.

B Cai1, M J Spencer, G Nakamura, L Tseng-Ong, J G Tidball.   

Abstract

Previous investigations have shown that cytotoxic T lymphocytes (CTLs) contribute to muscle pathology in the dystrophin-null mutant mouse (mdx) model of Duchenne muscular dystrophy through perforin-dependent and perforin-independent mechanisms. We have assessed whether the CTL-mediated pathology includes the promotion of eosinophilia in dystrophic muscle, and thereby provides a secondary mechanism through which CTLs contribute to muscular dystrophy. Quantitative immunohistochemistry confirmed that eosinophilia is a component of the mdx dystrophy. In addition, electron microscopic observations show that eosinophils traverse the basement membrane of mdx muscle fibers and display sites of close apposition of eosinophil and muscle membranes. The close membrane apposition is characterized by impingement of eosinophilic rods of major basic protein into the muscle cell membrane. Transfer of mdx splenocytes and mdx muscle extracts to irradiated C57 mice by intraperitoneal injection resulted in muscle eosinophilia in the recipient mice. Double-mutant mice lacking dystrophin and perforin showed less eosinophilia than was displayed by mdx mice that expressed perforin. Finally, administration of prednisolone, which has been shown previously to reduce the concentration of CTLs in dystrophic muscle, produced a significant reduction in eosinophilia. These findings indicate that eosinophilia is a component of the mdx pathology that is promoted by perforin-dependent cytotoxicity of effector T cells. However, some eosinophilia of mdx muscle is independent of perforin-mediated processes.

Entities:  

Keywords:  NASA Discipline Musculoskeletal; Non-NASA Center

Mesh:

Substances:

Year:  2000        PMID: 10793090      PMCID: PMC1876906          DOI: 10.1016/S0002-9440(10)65050-X

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. CIDD Study Group.

Authors:  J T Kissel; K L Burrow; K W Rammohan; J R Mendell
Journal:  Neurology       Date:  1991-05       Impact factor: 9.910

Review 2.  Current status of Duchenne muscular dystrophy.

Authors:  S T Iannaccone
Journal:  Pediatr Clin North Am       Date:  1992-08       Impact factor: 3.278

3.  In vivo immunomodulation by monoclonal anti-CD4 antibody. II. Effect on T cell response to myelin basic protein and experimental allergic encephalomyelitis.

Authors:  S Sriram; L Carroll; S Fortin; S Cooper; G Ranges
Journal:  J Immunol       Date:  1988-07-15       Impact factor: 5.422

4.  Dystrophin-deficient mdx muscle fibers are preferentially vulnerable to necrosis induced by experimental lengthening contractions.

Authors:  B Weller; G Karpati; S Carpenter
Journal:  J Neurol Sci       Date:  1990-12       Impact factor: 3.181

5.  Polymyositis mediated by T lymphocytes that express the gamma/delta receptor.

Authors:  R Hohlfeld; A G Engel; K Ii; M C Harper
Journal:  N Engl J Med       Date:  1991-03-28       Impact factor: 91.245

6.  Human eosinophils express functional interleukin 2 receptors.

Authors:  T H Rand; D S Silberstein; H Kornfeld; P F Weller
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

7.  Interaction of eosinophil granule major basic protein with synthetic lipid bilayers: a mechanism for toxicity.

Authors:  R I Abu-Ghazaleh; G J Gleich; F G Prendergast
Journal:  J Membr Biol       Date:  1992-06       Impact factor: 1.843

8.  Functional regeneration in the hindlimb skeletal muscle of the mdx mouse.

Authors:  J E Anderson; B H Bressler; W K Ovalle
Journal:  J Muscle Res Cell Motil       Date:  1988-12       Impact factor: 2.698

9.  Long-term benefit from prednisone therapy in Duchenne muscular dystrophy.

Authors:  G M Fenichel; J M Florence; A Pestronk; J R Mendell; R T Moxley; R C Griggs; M H Brooke; J P Miller; J Robison; W King
Journal:  Neurology       Date:  1991-12       Impact factor: 9.910

10.  Eosinophilic airway inflammation during exacerbation of asthma and its treatment with inhaled corticosteroid.

Authors:  L A Laitinen; A Laitinen; M Heino; T Haahtela
Journal:  Am Rev Respir Dis       Date:  1991-02
View more
  42 in total

1.  Markers of degeneration and regeneration in Duchenne muscular dystrophy.

Authors:  E Abdel-Salam; I Abdel-Meguid; S S Korraa
Journal:  Acta Myol       Date:  2009-12

Review 2.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

Review 3.  The expanding role(s) of eosinophils in health and disease.

Authors:  Elizabeth A Jacobsen; Richard A Helmers; James J Lee; Nancy A Lee
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

Review 4.  What do mouse models of muscular dystrophy tell us about the DAPC and its components?

Authors:  Charlotte Whitmore; Jennifer Morgan
Journal:  Int J Exp Pathol       Date:  2014-09-30       Impact factor: 1.925

Review 5.  Regulatory interactions between muscle and the immune system during muscle regeneration.

Authors:  James G Tidball; S Armando Villalta
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-03-10       Impact factor: 3.619

6.  Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-kappaB-inducing kinase and p38 mitogen-activated protein kinase: a potential role of MMP-9 in myopathy.

Authors:  Hong Li; Ashwani Mittal; Pradyut K Paul; Mukesh Kumar; Daya S Srivastava; Suresh C Tyagi; Ashok Kumar
Journal:  J Biol Chem       Date:  2008-12-11       Impact factor: 5.157

7.  Agent-based model illustrates the role of the microenvironment in regeneration in healthy and mdx skeletal muscle.

Authors:  Kelley M Virgilio; Kyle S Martin; Shayn M Peirce; Silvia S Blemker
Journal:  J Appl Physiol (1985)       Date:  2018-08-02

Review 8.  Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention.

Authors:  Nicholas P Evans; Sarah A Misyak; John L Robertson; Josep Bassaganya-Riera; Robert W Grange
Journal:  PM R       Date:  2009-08       Impact factor: 2.298

9.  Partial least squares based identification of Duchenne muscular dystrophy specific genes.

Authors:  Hui-bo An; Hua-cheng Zheng; Li Zhang; Lin Ma; Zheng-yan Liu
Journal:  J Zhejiang Univ Sci B       Date:  2013-11       Impact factor: 3.066

10.  Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta.

Authors:  Sylvia A Vetrone; Encarnacion Montecino-Rodriguez; Elena Kudryashova; Irina Kramerova; Eric P Hoffman; Scot D Liu; M Carrie Miceli; Melissa J Spencer
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.